Alza Corporation

Other

James B Eckenhoff, Deceased

Jeremy C Wright

Judy A Magruder

John R Peery

Sally A Tao

John J Leonard, Jr

Richard Lewis Cortese

James B Pike

Jonathan P Smith

Urano A Robinson

Cynthia L Stevenson

Steven J Prestrelski

John P Carr

Leslie A Holladay

Lyle Elmore Ziemann

Edward V Bourneuf

John M Sharockman

Iris K Leung

Felix A Landrau

Keith E Dionne

Scott D Lautenbach

Bonnie J Eckenhoff

Ed Bourneuf

The invention is directed to a device for delivering an active agent formulation for a predetermined administration period. An impermeable reservoir is divided into a water-swellable agent chamber and an active agent formulation chamber. Fluid from the environment is imbibed through a semipermeable plug into the water-swellable agent chamber and the active agent formulation is released through a back-diffusion regulating outlet. Delivery periods of up to 2 years are achieved.

Sustained delivery of an active agent using an implantable system

This invention relates to stable liquid aqueous formulations of peptide compounds at high concentrations. These stable formulations comprise at least about 10% peptide in water. They may be stored at elevated temperatures for long periods of time and are especially useful in implantable delivery devices for long term delivery of drug.

Aqueous formulations of peptides

This invention relates to stable non-aqueous protic formulations of peptide compounds. These stable formulations comprise peptide in non-aqueous protic solvent. They may be stored at elevated temperatures for long periods of time and are especially useful in implantable delivery devices for long term delivery of drug.

Non-aqueous protic peptide formulations

The present invention provides improved compositions for improving the chemical and physical stability of peptides and proteins. The invention provides a liquid beneficial agent formulation containing a liquid suspension comprising at least 5% by weight beneficial agent and having a viscosity and beneficial agent size which minimizes settling of the agent in suspension over the extended delivery period.

Peptide/protein suspending formulations

A method encompasses the substantially continuous electrotransport delivery of luteinizing hormone releasing hormone (LHRH), prologues, analogues, salts or mixtures thereof, preferably at a substantially constant rate, to a female mammal for the purpose of modifying its reproductive cycle. An electrotransport device substantially is suited for the continuous delivery of LHRH prologues, analogues, salts or mixtures thereof over an extended period of time to a mammal. The present technology may be successfully applied to the controlled breeding of mammals, such as thoroughbred race horses.

Method and device for controlling mammalian reproductive cycle

A delivery system is disclosed for delivering a fluid-sensitive active agent such as a somatotropin, or an analogue or derivative thereof, to an animal such as a bovine. The delivery system comprises a first wall section, a second wall section and a locking coupling therebetween. The coupled wall sections define a compartment, enclosing an active agent and an expandable driving member. Various embodiments of the locking coupling are disclosed.

Interlocking couplings for osmotic delivery devices

A delivery system (10) is disclosed for delivering a fluid-sensitive beneficial agent (7) such as a somatotropin, or an analogue or derivative thereof, to an animal such as a bovine. The delivery system comprises a wall that surrounds an internal compartment, said wall comprising a first wall section that limits the passage of fluid into the system and a second wall section that permits the passage of fluid into the system. An exit passageway is provided for delivering the beneficial agent an interior compartment (18) to the animal. The exit passageway is sealed with a wax seal (30) which is expelled through the passageway (13) as the internal pressure within the device (10) reaches a predetermined 'bursting' pressure. The passageway (13) is preferably sized to compensate for slight variations in the efflux of the beneficial agent and to maintaining a sufficient volumetric outflow rate of beneficial agent in order to minimize influx of biological fluids from the external environment back into the device once the seal (30) is expelled.

Implantable system for delivery of fluid-sensitive agents to animals

Locking couplings for osmotic delivery devices

Growing community of inventors

Los Altos, CA, United States of America

James B Eckenhoff, Deceased